中外健康文摘
中外健康文摘
중외건강문적
WORLD HEALTH DIGEST
2013年
9期
98-99
,共2页
三叉神经鞘瘤%伽玛刀治疗%三叉神经痛
三扠神經鞘瘤%伽瑪刀治療%三扠神經痛
삼차신경초류%가마도치료%삼차신경통
Trigeminal schwannoma%Gamma Knife Radiosurgery(GKS) Secondary%Trigeminal neuralgia
目的探讨伽玛刀治疗对三叉神经鞘瘤的临床疗效。方法回顾分析2005年5月到2012年7月本中心行伽玛刀治疗并随访的56例三叉神经鞘瘤病例,年龄最小27岁,最大70岁,平均年龄51岁,肿瘤平均体积6.5cm3,周边剂量12.0~14.0Gy ,平均13Gy,中心剂量26.0~32.5Gy,平均30.6Gy。结果随访时间6~48个月,平均36个月,通过MRI或CT影像学证实4例肿瘤基本消失,29例明显缩小,21例变化不明显,2例体积增大,肿瘤总控制率96%。43例患者的临床症状明显改善,8例患者临床症状无明显变化,5例临床症状持续加重。结论伽玛刀治疗对中小型三叉神经鞘瘤安全有效,能明显改善患者临床症状,保护颅脑神经功能。
目的探討伽瑪刀治療對三扠神經鞘瘤的臨床療效。方法迴顧分析2005年5月到2012年7月本中心行伽瑪刀治療併隨訪的56例三扠神經鞘瘤病例,年齡最小27歲,最大70歲,平均年齡51歲,腫瘤平均體積6.5cm3,週邊劑量12.0~14.0Gy ,平均13Gy,中心劑量26.0~32.5Gy,平均30.6Gy。結果隨訪時間6~48箇月,平均36箇月,通過MRI或CT影像學證實4例腫瘤基本消失,29例明顯縮小,21例變化不明顯,2例體積增大,腫瘤總控製率96%。43例患者的臨床癥狀明顯改善,8例患者臨床癥狀無明顯變化,5例臨床癥狀持續加重。結論伽瑪刀治療對中小型三扠神經鞘瘤安全有效,能明顯改善患者臨床癥狀,保護顱腦神經功能。
목적탐토가마도치료대삼차신경초류적림상료효。방법회고분석2005년5월도2012년7월본중심행가마도치료병수방적56례삼차신경초류병례,년령최소27세,최대70세,평균년령51세,종류평균체적6.5cm3,주변제량12.0~14.0Gy ,평균13Gy,중심제량26.0~32.5Gy,평균30.6Gy。결과수방시간6~48개월,평균36개월,통과MRI혹CT영상학증실4례종류기본소실,29례명현축소,21례변화불명현,2례체적증대,종류총공제솔96%。43례환자적림상증상명현개선,8례환자림상증상무명현변화,5례림상증상지속가중。결론가마도치료대중소형삼차신경초류안전유효,능명현개선환자림상증상,보호로뇌신경공능。
Objective The aim of this article was to assess the clinical effect of the gamma knife radiosurgery(GKS) for trigeminal schwannomas. Methods Between 2005 and 2012, patients with trigeminal schwannomas who were treated with GKS were followed up and reviewed in Yunnan Gamma Knife Treatment and Research Center. The minimum age was 27 years old, the maximum age was 70 years old, average was 51 years old. The average volume was 6.5cm3. The average peripheral dose was 13.0Gy and the central dose was 30.6Gy. Results The radiological follow-up period was 6 to 48 months, the average follow-up period was 36 months. With radiological follow-up 4 patients shoued nearly disappearance of tumor, 29 patients shoued reduction, 21 patients shoued no change, 2patients showed enlargement, and the overall tumor control rate was 95% . Improvement of presenting neurological symptoms was observed in 43 patients, stabilization of presenting neurological syndrome was observed in 8 patients, and continued injury of cranial nerve function was observed in 5 patients. Conclusion GKS provides an effective and safe management for small to moderate sized trigeminal schwannomas, and greatly improves the clinical symptoms.